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and in rats and improvea cardiac function in healthy volunteera. hi addition,
IGF has vaaodilator effects. We tested the tolerability and safety but alao the
acute hemodynamic effects of a single IGF infuaion in 8 patients (pta: 47 &
5 years, 1 female, 7 males) with mild to aevere chronic heart failure (mean
left ventricular ejection fraction 26 + 3’7., mean cardiac index [Cl] 2.6 +
0.4 Umin). Recombinant human IGF (60 mdkg of body weight) or matching
solvent were infused intravenously over 4 hours in a croasover, double
blind, randomized fashion on 2 subsequent days while regular medication
was given. Hemodynamics were continuously monitored by ballon-tipped
pulmonary and radial artery catheters, and ECG,respectively, before and
during 7 houra from the atarl of each infusion. IGF was well tolerated in all
pts and plaama glucose and electrolytes were unaffected by IGF.Right atrial,
pulmonary artery and pulmonary capillary wedge pressureawere unchanged
during the 2 study days. Compared to placebo, IGF reduced mean arterial
presaure by 2.6 mmHg [-3.95 to –1.25, p < 0.01] (valuea are means [957.
confidence interval]) and improved Cl by 0.36 Umin [+0.26 to +0.47, p <
0.01] through both an increase in heart rate of 5.8 beats/rein [+3.0 to +8.5,
p < 0.01] as well as of stroke volume index by 2.2 mUmin [+0.66 to +3.77,
p < 0.01], Conaequently, both syatemic and pulmonary vascular resistances
decreased by 204 [-247 to –160, p < 0.01] and 17.9 [–28.0 to –7.8, p <
0.01] dynes sec cm-5, respectively.Thus, acute IGF administration in these
pts is safe and improves cardiac performance seemingly through afterloed
reduction, It remains to be established whether the obaerved acute effects
are maintained and whether enhancement of myofibrila plays a role during
chronic therapy.
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Plaama levels of endothelin-1 are raiaed in heart failure and are thought to
contribute importantly to pulmonaty vascular resistance in this setting. We
administered endothelin-1 into a distal pulmonary artery of eight patients
with ventricular dysfunction with or without overt heart failure in an attempt
to atudy Imal pulmonary vascular effects. Local pulmonary flow using intra-
vascular Doppler ultrasound was asaessed in the first 4 patients. Central
haemodynamics were meaaured by thermodilution catheter and arterial line.
Endothelin-1 was infuaed at 1, 5 and 15 pmol/min. No side effecta occurred
but 2patienta did not receive the 15 pmol/min infusion due to a rise in syatolic
BP >20 mmHg or a fall in cardiac output of > 15%.
Systemic haemodynamic effects were obsewed with doses that caused
bcal pulmonary vascular effects. Cardiac index fell, doae dependently, from
2.38 +0.59 to 2.16+ 0.55 l/min/m2 (p =0.008) at the maximumadministered
dose. Mean arterial pressure rose from 98+ 7 to 108 +12 mmHg (p = 0.01)
but pulmonaty artery pressures (21 & 7 mmHg) and heart rate (67 + 12
beate/min) did not change. Systemic (1669+ 415t02032 + 478 dyn a cm-5;
p < 0.01) but not pulmona~ (154 * 49 to 147 + 45 dyn a cm-5) vascular
reaiatance rose and the pulmonary to ayatemicvascular resistance ratio fell.
Exogenous endothelin-1 causea systemic but not pulmonaty vasocon-
striction in patientswith Ieftventricular dysfunction. Increasedplasmaendothelin-
1 maybe a biological marker of rather than a cause of pulmona~ hyperten-
sion in heart failure.
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Alpha-l adrenoceptorstimulation inyoung normals invivoliberates release of
vaacdilatory proataglandina which antagonize the venoconstrictor response.
We hypothesized that in congestive heart failure (CHF) with endothelial
dysfunction there would be reduced release of vasodilatory prostaglandins
from theendothelium and therefore an increaaedvascular responaetoalpha-
1 stimulation.
Six CHF patients (LVEF 14.2 & 0.9%) and 6 age-similar normals were
studied on 2 daya uaing a hand vein technique to assess in vivo venous
responsiveneas without ayatemic effects. Graded 5 min local infusiona of
phenylephrine (6-12000 ng/min) were administered witha randomlyaelacted
separate infuaion (in the same vein) of either the proateglandin synthesis
blocker indomethacin (3 @rein) or aaline and dose response curves were
constructed of venoua distention at 45 mmHg. Endothelial function was
determined by acetylcholine (0.01-1.0 nmol/min).
Doae-dependent venoconstricfion was obaerved in all aubjects studied.
Maximum dilation to ecetylcholine was 57.3 + 9.7% for normals compared
to 10.6% & 3.0% for CHF patients. In normals, the entire phenylephrine
dose-response curve was significantly (p < 0.05) ahifted to the left with in-
domethacin. However, in CHF the phenylephrine doae-reaponae curve was
unaltered. Therefore the doae of phenylephrine to cause 50% venoconatrfc-
tion was decreased significantly with indomethacin compared with saline in
normals, but not in CHF (1.91 & 0.11vs. 2.77+0,12, p <0,05, normal; 2.37+
0.23 vs. 2.35 + 0.26, CHF; log ng/min & SEM). Thua, endothelial dysfunction
in CHF ia associated with a markedly blunted release in vivo of vasodila-
tory prostaglandins to an alpha-1 agoniat and this mechanism could result in
increased venoconatriction to sympathetic stimulation in patients with CHF.
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Synthetic B-type Natriuretic Peptide (aBNP) is identical to human BNP. In
patienta (pts)with hearffailure, pharmacologic doses of aBNP have favorable
effects during 4-6 hrs intravenous (IV) infusion, and with repeated IV boluses
over24 hrs. A multicenter, placebo-controlled, randomized, double-blind trial
was initiated to assess the effect of aBNP (15-60 ng/kgJmin)by continuous
IV infusion over 24 hrs vs placebo (PL) in pts with decompenaated heart
failure. Parameter included pulmona~ capillary wedge preaaure (PCWP,
principal endpoint), cardiac index (Cl), systolic blood presaure (SBP) and
heari rate (HR). Meaaurementa were taken at baseline (BL), 6, 10, and 24
hrs of infusion and at 4 hrs peat-infusion (28 hrs). An interim analyais was
performed including the first 50 pta (SBNP, n = 37; PL, n = 13); for this
analysia pts were not divided by dose.
Percentchangefrombaseline(sBNPIPL)
Infusion(hrs) Post (hrs)
6 10 24 4
PCWP -35/–2**-- –3,/+3**- –21/–lo** –1/–9
c1 +39/=1**”- +34/+3””- +261+8’” +14/0
HR –l/+7- -1/+13” +4/+14” +12/+lo**
SBP –a/-2** –4/–1 –61+2**- +1/-1
(**) BNPVS.baseline P less than Orequal to (0.01) (two-aided);“(-”)BNP VS. placeh p
less than or equsl to 0.05 (0.01) (two-sided)
aBNP reduced PCWP and improved Cl over 24 hra without major ad-
verse events, and appears to be a aafe potent agent for improving central
hemodynamics over a 24 hr period.
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Carperitide (aynthetic a-human atrfal natriuretic peptide, ANP) has bean
available as a therapeutic agent for acute heart failure in Japan. This study
was designed to assess the development of tolerance during continuous
administration of carperitide compared with nitroglycerin (NTG). Twelve pa-
tients hospitalized with acute heart failure (Forrestersubset 11)were randomly
assigned to two groups. After stabilization of hemodynamica (control phase),
intravenous infusion of ANP (ANP group, n = 6) or NTG (NTG group, n
= 6) was atatied at a rate of 0.1 @kg/rein, while diuretics and other va-
sodilators were discontinued. The optimum doaages of ANP and NTG wens
determined based on hemodynamic parameters (stage 1). Thereafter, ANP
or NTG was administered at the optimum doaage for 12 hours (stage 2). Pul-
monary artery pressure (PAP, mmHg) was measured every 2 hours. At the
same time, plasma cGMP (pmol/ml) was measured to evaluate the effect of
ANP,and platelet cGMP (pmol/lOg PLT)was meaaured to evaluate the effect
of NTG. In the control phase, there were no differences in hemodynamice,
plasma cGMP,or platelet cGMP between both groupa. In theatage 1, aystolio
PAP wee significantly decreased in the two groups (NTG group, 42 & 5 to
25 +5, p < 0.01; ANP group, 44+5 to 25 + 5, p < 0.01). Platelet cGMP in
the NTG group (0.76+ 0.12 to 2.42 * 0.24), and plaama cGMP in the ANP
group (from 8 + 2 to 36 + 9) were significantly incraased. However, in the
atage 2, PAP waa increased from 26 * 4 to 36 + 4 (p < 0.01), and platelet
cGMP was decreaaed from 2.42+ 0.24 to 1.41 + 0.11 (p< 0.01) in the NTG
group. In contrast, in the ANP group, PAP and plasma cGMP remained at
the values obaerved in the stage I (PAP: 25 + 5 to 26 + 5; plaama cGMP: 36
+ 8 to 40 + 6). Conclusion: Carperitide (ANP) improved hemodynamics in
patients with acute heart failure in the absence of development of tolerance
during continuous infusion.
